Amarin Announces Notification of Patent Allowances Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations

Loading...
Loading...
Amarin Corporation
AMRN
has published notification of a Notices of Allowance for Amarin's U.S. Patent Applications Serial Numbers 13/685,281, and 13/685,291, each titled "Stable Pharmaceutical Composition and Methods of Using Same." The claims in these allowed applications cover methods of lowering triglycerides by administering a pharmaceutical composition comprised of a mixture of free fatty acids, including EPA and/or DHA to varying degrees, to patients with severe hypertriglyceridemia (the MARINE population) and in patients with hypertriglyceridemia on concomitant statin therapy (the ANCHOR population). A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030. These applications are part of an expanding patent portfolio for Amarin with 38 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the United States.  About Amarin Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of
See full press release
Posted In: NewsGuidanceContractsManagementM&A
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...